Associated Genetic Biomarkers
NCI Definition: An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas. 
There is 1 clinical trial for neurofibromatosis, of which 1 is open and 0 are completed or closed. Of the trial that contains neurofibromatosis as an inclusion criterion, 1 is phase 3 (1 open).
NF1 is the most frequent gene inclusion criterion for neurofibromatosis clinical trials .
Sirolimus is the most common intervention in neurofibromatosis clinical trials.
Significant Genes in Neurofibromatosis
NF1 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and neurofibromatosis as inclusion criteria, 1 is phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.